In patients with Late-Onset Pompe Disease (LOPD), progressive respiratory muscle involvement leads to reduced pulmonary function, with respiratory failure the most common cause of mortality. Early disease manifestations include sleep-disordered breathing, which can be treated with non-invasive ventilation; however, progressive diurnal deficits can require invasive ventilation. To determine if pulmonary function tests (PFTs) predict the thresholds for ventilation and wheelchair use, a systematic literature review identified cross-sectional clinical patient data (N = 174) that was classified into ventilation and wheelchair cohorts. PFTs included maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), forced vital capacity (FVC), and vital capacity (VC), with vital capacities measured in the upright (-U) and supine (-S) positions. Receiver operating characteristic (ROC) curves were used to calculate cut-points (CP) and area under the curve (AUC). For all ventilation and mobility thresholds tested, ROC analyses demonstrated AUC values from 86-89% for MIP, 72-96% for MEP, and 74-96% for all vital capacity metrics. Thus, PFTs are useful in predicting the thresholds for nighttime ventilation, daytime ventilation, and wheelchair use, with MIP and VC-U having both high AUC values and consistency. The PFT mobility CPs were low (MIP CP = 0.9 kPa, MEP, CP = 2.6 kPa, VC-U CP = 19% predicted), suggesting an endurance component associated with wheelchair use.
Introduction
Late-Onset Pompe Disease (glycogen storage disorder type 2, acid maltase deficiency, LOPD) is a rare genetic disorder characterized by attenuated functionality of the enzyme acid alphaglucosidase. The resulting accumulation of glycogen in skeletal and respiratory muscles can result in myopathy, with progressive deterioration in both mobility and pulmonary function. As a heterogeneous disorder, clinical disease can present throughout life, from young childhood (>2 years) through adulthood. In over 70% of LOPD patients, respiratory failure is the most common cause of mortality [1, 2] . Longitudinal quality of life surveys have demonstrated reductions in the physical health domains in a step-wise manner with the addition of respiratory support (nighttime and daytime ventilators) and mobility assistance devices (e.g. wheelchairs) [3] [4] [5] .
With progressive decline of critical respiratory muscle function (e.g. diaphragm), sleep disordered breathing may arise with associated symptoms of morning headache, daytime somnolence and fatigue [6, 7] . Studies on sleep in patients with neuromuscular disorders (congenital muscular dystrophy, Duchenne muscular dystrophy, spinal muscular atrophy type I-II, limb-girdle dystrophy, late-onset Pompe disease/acid maltase deficiency, nemaline myopathy, hereditary motor and sensory neuropathy type I, centronuclear myopathy, myotonic dystrophy, and non-classified myopathy) have suggested that the onset of both sleep-disordered breathing (SDB) and nocturnal hypoventilation (NHV) can be predicted with daytime pulmonary function measurements (e.g. inspiratory vital capacity, IVC; maximum inspiratory pressure, MIP) [8] [9] [10] [11] . In neuromuscular disorders, the introduction of nighttime ventilation has been shown to significantly improve the restfulness of sleep (daytime sleepiness; morning headache) and correct daytime hypoxemia and hypercapnia [12, 13] .
In addition to sleep studies, pulmonary function tests (PFT), specifically MIP and FVC, have been used to establish the need and financial reimbursement for nocturnal mechanical ventilation in patients with neuromuscular disorders [14, 15] . While the health insurance systems in the United States and the United Kingdom have defined PFT criterion for reimbursement of nocturnal ventilation [15, 16] , these have not been adopted internationally and there are no proposed criteria for daytime ventilation. Since the implementation of nocturnal, and subsequently, daytime ventilation are important milestones in the progression of LOPD, the present study was designed to evaluate if non-invasive pulmonary function tests (PFTs) can be used to describe the predictive thresholds for both nocturnal and diurnal ventilator usage. In addition, as respiratory function can affect endurance and mobility, this study also examined the ability of PFTs to describe the predictive threshold between a mobile state and wheelchair usage.
Methods

Search strategy
Clinical studies reporting both pulmonary function metrics and ventilator use of individual LOPD patients were identified using electronic searches of both EMBASE and MEDLINE database on October 7, 2014. The search terms included the following terms: ("pompe" OR "glycogen storage disease type 2" OR "acid maltase" OR "glycogenosis") AND ("respiratory" OR "ventilator" OR "pulmonary"). Using the SCOPUS database, additional studies were identified from subsequent articles that had cited the initial list of clinical studies that had passed the screening process.
To identify only individuals with late-onset disease, clinical studies and case reports of patients ≥2 years with both pulmonary function test (PFT) results and a description of ventilator usage were included. Exclusion criteria also comprised studies reporting on animal models, infantile Pompe disease (<2 years), other diseases, disease management guidelines, diagnostic tools, genotype-phenotype studies, and articles written in languages other than English. The selection criteria, shown in Fig. 1 , identified 34 studies with patient level data reporting at least 1 PFT and a description of ventilator status [6, .
Data identification and analyses
Individual data were identified from the included clinical studies. Averaged values were not used. Pulmonary function data included two measures of respiratory muscle strength, maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), as well as four measures of lung volume, vital capacity in the upright (VC-U) and supine (VC-S) positions, forced vital capacity in the upright (FVC-U) and supine (FVC-S) positions. The respiratory muscle strength measurements (MIP, MEP) were analyzed in terms of pressure (kPa), while the lung capacity metrics (VC, FVC) were analyzed as percent of predicted values (% predicted). The respiratory muscle strength measurements are typically reported as absolute values and not normalized for age or gender. These metrics were the most commonly reported tests in the literature, providing sufficient data for these analyses. Data were excluded if descriptions of ventilator status for individual patients were inadequate. Clinical data from patients who were treated and untreated with enzyme replacement therapy (ERT) were included, with the assumption that treatment may alter the trajectory of progression but not the relationship between each PFT parameter and ventilator/ambulation status. To assess the degree to which treatment (or lack thereof) may influence these analyses, a statistical comparison of the treated vs. non-treated patients within each cohort was also performed.
Ventilator status was determined by either a written description in the study (no ventilation, nighttime ventilation, or daytime ventilatory assistance) or a description of the ventilator time usage per day (with ≤ 12 hours representing nocturnal ventilation and > 12 hours representing daytime use). Preference between these two methods was given to the written description in the text. To incorporate the possible addition of ventilation during longitudinal progression, up to 4 data points per individual were included, with a minimum of 3 months between measurements.
To determine the ability of PFTs to predict the thresholds in ventilator status, clinical data were assigned to 1 of 3 cohorts, as defined with no ventilation (none), nighttime ventilation (night), or daytime ventilation (day). These cohorts were analyzed using receiver operating characteristic (ROC) curves, determining the cut point (CP, from the maximum likelihood ratio), the area under the curve (AUC), as well as the sensitivity and specificity values. Analyses were performed with GraphPad Prism version 6.05 (GraphPad Software, La Jolla, CA, USA). Each PFT was considered separately, evaluating the hypothesis that each metric could independently predict these threshold points. AUC values of 100% represent a perfect differentiation between the groups.
In addition, an analysis using only a single point from each patient was also performed to determine if there was an inherent bias with the inclusion of longitudinal data. As VC and FVC have been used interchangeably in the literature, additional analyses were performed using combined data sets for VC-U and FVC-U, as well as VC-S and FVC-S. For individual patient data reporting both a VC and an FVC metric, the larger value was used in the combined analyses.
To determine the ability of PFTs to differentiate ambulation and wheelchair use, well-characterized clinical data were assigned to 1 of 2 cohorts (mobile or wheelchair) and also analyzed using ROCs. Wheelchair status was defined by a written description of wheelchair usage, a description stating that a sixminute walk test (6MWT) was not feasible, or a Walton score ≥ 7. Mobile status was defined by a written description of mobility, a value for the 6MWT, or a Walton score < 7. Individual patient data with inadequately characterized descriptions of mobility were classified as unknown and not used for this mobility analysis.
Results
Patient characteristics
From the 34 included studies, clinical data describing ventilator status and at least one PFT were identified for 174 individual patients (N), with characteristics shown in Table 1 . With the inclusion of up to 4 data points per individual patient with at least a 3-month separation between observations, a total number of observations (n) of 267 were identified and used in these analyses. The ages of the patients at the time of observation are also shown in this table, as well as the countries that the studies originated in. As these reported data had been de-identified, there was the possibility that individual patient data may have been represented in multiple reports. To determine if there were duplicate records, patient data in different studies from the same authors and/or within the same country were compared using gender and age. Using this method, there were no individual data that overlapped. To evaluate a possible effect that treatment may have on these analyses, the clinical data points were also characterized as untreated or treated with ERT. Within each PFT (MIP, MEP, VC-U, FVC-U), data were grouped according to treatment and analyzed with a student t-test to determine if there were statistically relevant differences that may affect the ROC analyses. For the observational data, 164 data points were obtained for untreated and 78 data points were identified as ERT treated. The remaining undefined data were not used in this analysis. In comparing the treated vs. untreated data, the p-values from the student t-test for the three ventilation cohorts (none; night; day) were calculated for MIP (0.55; 0.96; 0.23), 
Predictive thresholds for ventilator use
As shown in Table 2 , non-invasive PFTs were able to describe the two predictive thresholds for ventilator use with high AUC values. The number of observations (n) used for each parameter are also provided in this table. A visual representation of the data points and ROC curves for the 6 parameters (MIP, MEP, VC-U, VC-S, FVC-U, FVC-S) are shown in Fig. 2. 
Threshold for nighttime ventilation
In differentiating the no ventilation and nighttime ventilation groups, 5 metrics (MIP, FVC-U, VC-U, FVC-S, VC-S) were able to predict these thresholds with AUC values ≥83%. For the two respiratory muscle strength metrics (MIP, MEP), only MIP was able to describe the predictive threshold between the no ventilation and nighttime ventilation groups with high differentiation (CP = 2.8 kPa, AUC = 89%, p < 0.0001). For MEP, there was considerable overlap between the no ventilation and the nighttime ventilation groups, as characterized by a moderate AUC value (CP = 3.0 kPa, AUC = 72%, p = 0.03).
In examining the lung capacity tests, the cut points for VC-U (45% predicted) and FVC-U (39% predicted) for the thresholds between the no ventilation and nighttime ventilation groups had similar values. In the combined analysis of FVC-U and VC-U, the cut point (40% predicted) was between the values determined for the 2 individual metrics. For the supine vital capacity measurements, VC-S (CP = 25% predicted) provided good differentiation between the no ventilator and nighttime ventilator groups. Unexpectedly, a lower AUC value was noted for FVC-S which may reflect the relative lack of data reported for this parameter. Supine measurements can be difficult to obtain in LOPD, as this position can result in severe dyspnea and may be intolerable. Consistent with the reported diaphragmatic weakness in this disorder, the cut points for vital capacity in the supine position were lower than the corresponding values determined in the upright position.
Threshold for daytime ventilation
In determining the predictive thresholds between the nighttime ventilation and daytime ventilation groups, five parameters (MIP, MEP, FVC-U, VC-U, VC-S) were, to varying degrees, able to differentiate these two states with AUC values ≥80%, as shown in Table 2 . There were not enough data points to evaluate the predictive threshold for FVC-S. The predictive thresholds between the nighttime and daytime cohorts for these parameters were all distinctly lower than the values determined for the thresholds between no ventilation and nighttime ventilation, indicating that lung function decreased with disease progression.
For the respiratory muscle strength metrics, MIP described both ventilation thresholds with the same AUC values (89%). For MEP, the ability to differentiate the two ventilator predicative thresholds was distinctly different, as shown in Table 2 .
With the exception of FVC-S (there were too few data points for this analysis), the lung capacity tests were able to predict the threshold points between nighttime ventilation and daytime ventilatory assistance groups. Unexpectedly, the AUC values for FVC-U were lower for the threshold for daytime assistance (80%) than the nighttime value (87%). This decrease was not observed with the VC-U values alone. However, in the combined analysis with both FVC-U and VC-U, the AUC values were different for the thresholds between the no ventilation and nighttime groups (92%) and the nighttime and daytime ventilation groups (84%). To determine if there was a bias with the inclusion of longitudinal data, an ROC analysis using only one data point from each included patient was also performed. For individuals with multiple values, the lowest value was used in this additional analysis. For the two ventilator analyses (none and night groups; night and day groups), the single data point analysis produced values for MIP (CP = 2.5 kPa, AUC = 89%; CP = 1.2 kPa, AUC = 90%), MEP (CP = 3.0 kPa, AUC = 67%; CP = 2.5 kPa, AUC = 92%), FVC-U (CP = 39% predicted, AUC = 86%; CP = 20% predicted, AUC = 80%), VC-U (CP = 45% predicted, AUC = 96%; CP = 18% predicted, AUC = 96%), FVC-S (CP = 31% predicted, AUC = 88%; no available data for daytime analysis), and VC-S (CP = 25% predicted, AUC = 96%; CP = 11% predicted, AUC = 89%), respectively. The similarities between these values and the calculated values using the entire data set, as reported in Table 2 , suggest that there was minimal/no bias with the inclusion of longitudinal data.
Predictive threshold for wheelchair use
To determine if measures of lung function could be used to predict the threshold between the mobile and wheelchair groups, the identified data were grouped into 2 cohorts (mobile; wheelchair) and analyzed with ROC curves. As shown in Table 3 , the pulmonary function parameters were able to differentiate these two groups. Data points and ROC curves for these analyses are also shown in Fig. 3A-F .
Among the PFTs, the respiratory muscle strength metrics (MIP, MEP) had the highest AUC values of 86% and 95%, respectively. With the exception of FVC-S (not enough data points in the wheelchair cohort for an analysis), the lung capacity metrics were also able to predict these thresholds. In contrast with the ventilation analyses, the predictive thresholds for the vital capacity measurements for the upright and supine positions were not distinctly different. In addition, the cut point values were also quite low and well below the values observed for the predictive threshold values determined for the no ventilation to nighttime ventilatory support groups, supporting a discordance between progression of respiratory muscle vs. peripheral skeletal muscle weakness.
Discussion
The addition of ventilator assistance and wheelchair use are significant events in the progression of LOPD. In a study on the quality of life of 210 LOPD patients, the addition of ventilation and/or wheelchair use was associated with a maximal negative impact in the physical functioning scores on the SF-36 survey, with the these events ranked in the following order: ventilator and wheelchair use > > ventilator only > wheelchair only [3] . For these important events, clinically relevant surrogate tests to appropriately monitor disease progression would be beneficial. The tight associations observed between pulmonary function metrics and ventilator/wheelchair use suggest that lung function parameters may be useful in monitoring the possible onset of these events.
Prior studies in patients with primary myopathies have evaluated the relationship between respiratory function and presence of sleep disordered breathing and diurnal respiratory failure. These studies demonstrated that as respiratory dysfunction progresses patients develop sleep disordered breathing which progresses to nocturnal hypoventilation, manifest as hypercapnia during sleep, and eventually development of diurnal respiratory failure. The cut points identified in these prior studies for the presence of nocturnal hypoventilation and diurnal respiratory failure coincides with the cut points identified in the present study for the nighttime and daytime ventilation groups, respectively. Of importance, these studies demonstrated that the onset of sleep disordered breathing occurs at rather high levels of respiratory function (vital capacity < 60% predicted, MIP < 4.5 kPa), indicating that the onset of sleep disordered breathing can be easily missed without direct assessment of respiration and/or gas exchange during sleep. The present study extends these observations to a diverse group of patients with LOPD from many countries and by identification of thresholds for supine vital capacity to account for the diaphragmatic weakness that is characteristic of LOPD.
In the present study, data for vital capacity were collected from published studies that used differing measurement techniques (e.g. FVC, slow VC, IVC). Whereas the measured vital capacity will not vary by the respiratory maneuver in healthy subjects, lower values for FVC can be observed in patients with airway obstruction (e.g. asthma) [50] . In our study, separate analyses were performed for FVC vs. VC. Although differences for the cut points were observed, they were minimal and likely reflect variability in the underlying populations used in these studies. Since, to the best of our knowledge, there are no reports suggesting that respiratory Table 3 Prediction of wheelchair use by non-invasive pulmonary function tests in LOPD.
Parameter
Threshold between mobile and wheelchair groups Dash (-) indicates that there were not enough data points reported to perform this analysis. n: the number of observations assigned to each cohort. Cut point: value with the highest likelihood ratio from the ROC analysis. U: measurements performed in the upright position. S: measurements performed in the supine position. AUC (%): values of 100% represent a perfect discrimination between the 2 groups. dysfunction in LOPD is characterized by airway obstruction, the combined analysis which includes data from all studies may provide the most accurate assessment of the cut points. Pulmonary function test criterion, in particular MIP and FVC, have been used as requirements for funding the equipment for non-invasive ventilation. In the United States, the Centers for Medicare and Medicaid (CMS) requirements for funding ventilation assistance can be satisfied for neuromuscular disorders with a criterion of either FVC < 50% predicted or MIP < 60 cmH2O (5.9 kPa) [15] . These criteria were reportedly derived from studies in patients with amyotrophic lateral sclerosis (ALS) [51, 52] . Even with these recommendations, Mendoza et al. (2007) found that patients with ALS reached the MIP criterion 4-6.5 months earlier than the FVC criterion [52] . While our study did not have sufficient data for a longitudinal analysis, our data for LOPD patients did suggest that nocturnal and daytime mechanical ventilator support was more tightly linked to MIP values less than 60 cmH2O (5.9 kPa) than to values of FVC or VC in the upright position below 50% predicted. Analysis of individual patient values revealed that 31% (17/55) of the LOPD patients using nighttime ventilation had vital capacity measurements exceeding 50% predicted, indicating that a large population of patients would not qualify for ventilation reimbursement using either the CMS or NICE criteria in the absence of additional measurement of respiratory muscle strength. In contrast, only 8% (3/37) of the LOPD patients with nighttime ventilation had MIP values exceeding 60 cmH2O (5.9 kPa). Even for the more stringent NICE criterion of MIP < 40 cmH2O (3.9 kPa), only 16% (6/37) of the LOPD patients did not meet these requirements. In addition, although all patients treated with nocturnal ventilation demonstrated values for VC or FVC in the supine position below 50% predicted, it is unclear if these supine measurements would satisfy either the CMS or NICE guidelines, especially if simultaneous upright values were above this threshold. With these guidelines for ventilation reimbursement, these data demonstrate that many subjects will achieve the MIP criteria before the VC criteria.
The predictive threshold for VC for nighttime ventilation was similar to the criteria that justifies reimbursement by CMS, suggesting a potential bias. However, this study included patients from multiple countries, and reimbursement thresholds were only in place for the US and recently (since 2010) for the UK (National Institute for Health and Care Excellence, NICE). There were only a total of 9 individuals in this study who were from either the US or the UK, as shown in Table 1 . While not excluding the possibility that physicians in the other countries could have used the CMS/NICE guidelines, reimbursement of NIV therapy in the majority of patients included in our study would not have been contingent on the measured lung function. Moreover, approximately 1/3 of the patients receiving nocturnal ventilation had measured values of vital capacity exceeding 50% predicted, indicating that other criteria for initiating therapy had clearly been used. It is also unlikely that MIP criteria were used in all of these subjects, as this parameter was monitored less frequently in the patients included in our study. Although the retrospective nature of our study does not allow definitive determination of the indication for nocturnal ventilation in individual patients, the thresholds that we determined were highly reproducible despite variable locations/countries and prescribing physicians. Lastly, the thresholds we identified for nocturnal ventilation are physiologically plausible, as these values coincide with the level of respiratory function where hypoventilation first manifests during sleep in patients with respiratory muscle weakness, as discussed previously.
As a heterogeneous disorder, the progressive muscle involvement in LOPD can vary substantially with diverse requirements for mobility and respiratory assistive devices [53] . While wheelchair assistance is generally thought to be related to decreased function of the motor muscles, there may be a respiratory or endurance component that contributes to the decision to use a wheelchair. Case study observations have suggested that respiratory distress or exertional dyspnea may be factors in wheelchair use [21, 22] . Our analysis does indicate that PFTs (MIP, MEP, FVC-U, VC-U, VC-S) can be used to distinguish mobility from wheelchair use. In particular, our analysis suggested that the threshold for wheelchair use coincided with the need for daytime ventilation assistance. Although speculative in nature, the use of predictive thresholds for wheelchair use is a novel finding, which warrants additional investigation. We cannot exclude, for example, a direct influence of the seated position and/or scoliosis in the evolution of respiratory status (e.g. the lack of exercise may, by itself, decrease pulmonary function). In addition, the equipment requirements for daytime ventilation may influence the use of a wheelchair for mobility. Prospective, longitudinal studies to evaluate the multiple factors that may influence wheelchair use would be needed to fully characterize this mobility transition.
Our study may be limited by the heterogeneity of the reported data. Different methodologies for determining the PFTs may contribute to variability in these analyses. In addition, as a cross-sectional study, the individual requirements for initiating ventilation and wheelchair use cannot be discerned. Longitudinal studies monitoring PFTs, SDB, nocturnal hypoventilation, and diurnal respiratory failure, as well as ventilation and wheelchair events, would be beneficial. Previous studies have also shown a strong association between pulmonary function and scoliosis in LOPD patients [54] . In a Pompe registry, scoliosis was reported in the majority (62.5%) of wheelchair users for all age groups. Also, a larger percentage of patients with scoliosis required respiratory support than patients without scoliosis (44% vs. 27.2%, respectively). In the included studies, data describing the presence and degree of scoliosis were uncommon, precluding an assessment of the impact of scoliosis on the entire study. It should be noted, however, that scoliosis may contribute to both the observed reduced pulmonary function and wheelchair use.
Conclusion
In LOPD, the addition of ventilation and/or wheelchair use are significant events in disease progression, negatively affecting quality of life. Our findings suggest that measures of pulmonary function (MIP, MEP, FVC, VC) can act as surrogate markers to predict the thresholds for ventilation (nighttime; daytime). MIP and VC in the upright position had high AUC values and consistency in predicting these thresholds. In comparison to sleep studies reported in the literature, the threshold points for nighttime ventilation coincided with values that are associated with presence of nocturnal hypoventilation in primary myopathies. In an exploratory analysis on a possible relationship between respiratory function and mobility, pulmonary function tests were also associated with wheelchair use. Pulmonary function tests may aid in identifying patients at risk for ventilation and monitoring disease progression in patients with late-onset Pompe disease.
